OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX) in a research note released on Monday morning. The brokerage issued a sell rating on the stock.

OncoCyte Trading Down 1.7 %

NASDAQ:OCX opened at $2.93 on Monday. The business’s 50-day moving average is $3.02 and its 200 day moving average is $3.10. OncoCyte has a 12 month low of $2.08 and a 12 month high of $7.40.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Raymond James Financial Services Advisors Inc. acquired a new position in OncoCyte during the 1st quarter valued at about $25,000. DCF Advisers LLC grew its stake in OncoCyte by 107.0% during the 1st quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock valued at $37,000 after purchasing an additional 13,000 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in OncoCyte during the 2nd quarter valued at about $25,000. Balyasny Asset Management LLC grew its stake in OncoCyte by 389.9% during the 3rd quarter. Balyasny Asset Management LLC now owns 52,887 shares of the company’s stock valued at $39,000 after purchasing an additional 42,091 shares during the last quarter. Finally, LPL Financial LLC grew its stake in OncoCyte by 58.1% during the 2nd quarter. LPL Financial LLC now owns 108,816 shares of the company’s stock valued at $98,000 after purchasing an additional 40,000 shares during the last quarter. 55.35% of the stock is owned by institutional investors.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.